Varicella-Zoster Virus–Specific Immune Responses in Elderly Recipients of a Herpes Zoster Vaccine

BackgroundA double-blind, placebo-controlled trial that involved 38,546 subjects ⩾60 years old demonstrated efficacy of a high-potency live-attenuated Oka/Merck varicella-zoster virus (VZV) vaccine. The trial included an immunology substudy to determine the relationship of VZV-specific immune respon...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Levin, M. J, Oxman, M. N, Zhang, J. H, Johnson, G. R, Stanley, H, Hayward, A. R, Caulfield, M. J, Irwin, M. R, Smith, J. G, Clair, J, Chan, I. S. F, Williams, H, Harbecke, R, Marchese, R, Straus, S. E, Gershon, A, Weinberg, A
Format: Artigo
Idioma:Inglês
Publicat: The University of Chicago Press 2008
Matèries:
Major Articles And Brief Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4014857/
https://ncbi.nlm.nih.gov/pubmed/18419349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1086/528696
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars